MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2016 International Congress

    Conversion of patients from immediate release carbidopa-levodopa (IR CD-LD) and sustained release carbidopa-levodopa (SR CD-LD) to extended-release carbidopa-levodopa (ER CD-LD) in clinical practice

    S.J. LoRusso, B. Ouyang, B.R. Barton (Chicago, IL, USA)

    Objective: To evaluate the real-world response of patients who are converted from IR CD-LD and SR CD-LD to ER CD-LD in an academic practice. Background:…
  • 2016 International Congress

    Developing a new home monitoring device for dyskinesia in Parkinson’s disease

    J.E. Alty, J. Cosgrove, M.A. Lones, S. Jamieson, P. Duggan-Carter, C. Peacey, C. Wicks, R.F. Naylor, A.J. Turner, S.L. Smith (Leeds, United Kingdom)

    Objective: To evaluate how accurately a new device can discriminate different clinical severities of dyskinesia from non-dyskinetic movements in patients with Parkinson's disease (PD). Background:…
  • 2016 International Congress

    Real world conversion of levodopa to a novel extended release levodopa preparation: Determining predictors and dose ratios

    W. Ondo, P. Coss, M. Christie (Houston, TX, USA)

    Objective: To determine predictors of response and conversion ratios for a novel extended release levodopa preparation. Background: A new extended release levodopa preparation, Rytary®, has…
  • 2016 International Congress

    Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience

    E. Pekkonen, J. Lyytinen, O. Lindström, L. Kylänpää, M. Udd (Helsinki, Finland)

    Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…
  • 2016 International Congress

    A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients

    K. Kieburtz, C.W. Olanow, Y. Cohen, S. Oren (Rochester, NY, USA)

    Objective: To evaluate the efficacy, safety & tolerability of continuous subcutaneous infusion regimens of ND0612H. Background: L-dopa remains the most effective PD medication, however oral…
  • 2016 International Congress

    Objective measures of Parkinsonian motor symptoms using a continuously worn smartwatch

    N. Fixler, L. Reitblat, A. Wagner, S. Cohen, M. Afek, P. Bonato, J.F. Daneault, N. Golabchi, S. Moore, A. Patel, C. Cho, L. Bataille (Petach Tikva, Israel)

    Objective: To determine whether smartwatch sensor data correlates with clinician-measured Parkinson's disease symptoms. Background: Data collected with smartwatches could be used for long-term, continuous assessment…
  • 2016 International Congress

    Automated Telehealth Diagnostics for Remote Parkinson Monitoring

    D.A. Heldman, D.A. Harris, T. Felong, B. Goldberg, J.P. Giuffrida, E.R. Dorsey, M.A. Burack (Cleveland, OH, USA)

    Objective: To clinically assess and evaluate the impact of automated telehealth diagnostics on patients with Parkinson's disease (PD). Background: A single evaluation in a clinical…
  • 2016 International Congress

    Multidisciplinary Parkinson rehabilitation in the Netherlands: The effectiveness of points of Parkinson (POP)

    E.T. Steendam-Oldekamp, W.A.W.F. Rutgers, T. van Laar (Groningen, Netherlands)

    Objective: To analyze the effect of the POP rehab program for advanced PD patients on motor- and non-motor symptoms up to 2 years and determine…
  • 2016 International Congress

    Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease – A randomized, crossover infusion study

    M. Senek, D. Nyholm (Uppsala, Sweden)

    Objective: To compare the systemic levodopa exposure during administration of levodopa-entacapone-carbidopa (LECIG) intestinal gel with levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson's disease (PD) patients.…
  • 2016 International Congress

    Continuous subcutaneous delivery of solubilized carbidopa improves the pharmacokinetic profile of levodopa

    R. Shaltiel-Karyo, E. Zawoznik, I. Weinstock, M. Nemas, Y. Caraco, P.A. LeWitt, S. Oren, O. Yacoby-Zeevi (Rehovot, Israel)

    Objective: To characterize the peripheral pharmacokinetics and CNS metabolism of levodopa during continuous subcutaneous delivery of solubilized carbidopa. Background: Although many commercial levodopa formulations include…
  • « Previous Page
  • 1
  • …
  • 49
  • 50
  • 51
  • 52
  • 53
  • …
  • 57
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley